CN110554192A

CN110554192A - Application of LIMCH1 autoantibody detection reagent in preparation of lung cancer screening kit

Info

Publication number: CN110554192A
Application number: CN201910563593.5A
Authority: CN
Inventors: 李为民; 张立
Original assignee: West China Precision Medicine Industrial Technology Institute; West China Hospital of Sichuan University
Current assignee: West China Precision Medicine Industrial Technology Institute; West China Hospital of Sichuan University
Priority date: 2019-06-26
Filing date: 2019-06-26
Publication date: 2019-12-10
Anticipated expiration: 2039-06-26
Also published as: CN110554192B

Abstract

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a LIMCH1 autoantibody detection reagent in preparation of a lung cancer screening kit. The invention discovers for the first time that the autoantibody level of the LIMCH1 protein in the serum of a lung cancer patient is obviously higher than that of a healthy patient. According to the invention, the reagent for detecting the LIMCH1 protein autoantibody is used for preparing the lung cancer screening kit, so that the effective screening of the lung cancer can be realized.

Description

Application of LIMCH1 autoantibody detection reagent in preparation of lung cancer screening kit

Technical Field

The invention relates to the field of in-vitro diagnostic reagents, in particular to an application of a LIMCH1 autoantibody detection reagent in preparation of a lung cancer screening kit.

background

lung cancer is one of the most common malignant tumors in the world, the morbidity and mortality of the lung cancer are on the rising trend year by year, the morbidity is at the top of the world at present, and the health and the life of human beings are seriously threatened.

The lung cancer is a disease good in occult, clinical symptoms are often shown only when the disease develops to the advanced stage, 70-80% of lung cancer patients are already at the middle and advanced stages when the lung cancer symptoms are diagnosed, cancer cells are diffused, the best curing time is missed, and the five-year survival rate is low. For early-stage lung cancer patients, the survival rate and the survival quality of the patients can be greatly improved by 5 years and more through timely treatment. Early diagnosis of lung cancer and effective screening are therefore of paramount importance.

The screening of the lung cancer refers to that the conventional physical examination is carried out on people without lung cancer related symptoms, and the lung cancer is found in time before the symptoms appear. If the lung cancer molecular marker in the plasma can be found, the molecular marker has important significance for prompting a clinician to take relevant treatment measures or decisions for a patient at an early stage.

Autoantibodies are antibodies produced by the body to self-organs, cells or cellular components. At present, autoantibodies to certain proteins have become markers for lung cancer, such as: p53, NY-ESO-1, CYFRA, etc. (Tang Z-M, Link Z-G, WangC-M, Wu Y-B, Kong J-L (2017) Serum tune-associated autoimmune agents as diagnostic biologics for lung cancer: A systematic review and meta-analysis. PLoS ONE 12(7): e 0182117).

LIMCH1(Ensembl: ENSG00000064042 MIM:617750, LIM and Calponin-homology domains 1) is a LIM and Calponin homology domain, and is widely expressed in lung (RPKM 19.3), spleen (RPKM14.7) and other 20 tissues. At present, no report related to the LIMCH1 protein autoantibody exists, and no prior art related to lung cancer exists.

disclosure of Invention

The invention aims to provide a novel autoantibody lung cancer marker and application of a detection reagent of the marker in preparation of a lung cancer screening kit.

The technical scheme of the invention comprises the following steps:

The application of a reagent for detecting the LIMCH1 protein autoantibody in preparing a lung cancer screening kit.

As the application, the reagent for detecting the LIMCH1 protein autoantibody is a reagent for enzyme-linked immunosorbent assay or a combined immunoassay reagent.

As for the application, the reagent for detecting the LIMCH1 protein autoantibody is a western blot reagent.

As mentioned above, the reagent for detecting the LIMCH1 protein autoantibody is a reagent for a protein chip detection method.

As for the above-mentioned application, the reagent for detecting the LIMCH1 protein autoantibody is a reagent for detecting the LIMCH1 protein autoantibody in human serum.

A lung cancer screening kit comprises a reagent for detecting an autoantibody of LIMCH1 protein.

As the kit, the reagent for detecting the LIMCH1 protein autoantibody is a reagent for enzyme-linked immunosorbent assay or an enzyme-linked immunoassay reagent.

According to the kit, the reagent for detecting the LIMCH1 protein autoantibody is a western blot reagent.

As the kit, the reagent for detecting the LIMCH1 protein autoantibody is a reagent for a protein chip detection method.

As the kit, the reagent for detecting the LIMCH1 protein autoantibody is a reagent for detecting the LIMCH1 protein autoantibody in human serum.

The invention provides a new lung cancer screening marker and a new lung cancer screening kit, which can realize effective screening of lung cancer; and the serum can be used as a detection sample, so that the harm to a patient is low. The invention has good application prospect.

Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.

The foregoing aspects of the present invention are explained in further detail below with reference to specific embodiments. It should not be understood that the scope of the above-described subject matter of the present invention is limited to the following examples. All the technologies realized based on the above-mentioned contents of the present invention are within the scope of the present invention.

Hereinafter, "LIMCH 1 autoantibody" refers to "LIMCH 1 protein autoantibody".

Drawings

FIG. 1: lung cancer patients (LC), benign lung Disease (DC), healthy control (NC) serum levels of lichh 1 autoantibodies were compared.

FIG. 2: ROC analysis of lung cancer patients (LC) and benign lung Disease (DC).

FIG. 3: lung cancer patients (LC) were analyzed by ROC with healthy controls (NC).

Detailed Description

EXAMPLE 1 relationship of LIMCH1 autoantibodies to Lung cancer in plasma

First, clinical data

30 lung cancer patients, 29 lung benign diseases (non-malignant tumors such as tuberculosis and hamartoma) and 30 healthy controls are selected, and the basic information is as follows:

Basic information	Patients with lung cancer	Benign lung disease	Healthy controls
				Number of people	30	29	30
Age (age)	58±10.5	46.5±10.0	42±8.9
				Proportion of male	20(66.7)	12(41.4％)	13(46.7％)

Second, detection principle

The human protein customized chip HuProt ^TM is fixed with LIMCH1 protein, after incubation with serum, LIMCH1 autoantibodies (mainly including IgG and IgM antibodies and also some other types of antibodies) in the serum can be bound, unbound antibodies and other proteins are removed by cleaning, anti-human IgM fluorescent labeled secondary antibody (cy5 labeled and red) and anti-human IgG fluorescent secondary antibody (cy3 labeled and green) are used for detection, signals are read by a fluorescence scanner, and the strength of the signals is positively correlated with the affinity and the quantity of the antibodies.

Third, method

The reagents used in this section were as follows:

1) Rewarming: taking out the chip from a refrigerator at-80 deg.C, putting in a refrigerator at 4 deg.C for rewarming for half an hour, and then putting in room temperature for rewarming for 15 min;

2) And (3) sealing: fixing 14 blocks in the rewarming chip, adding a sealing liquid into each block after fixing, placing on a side swing table, and sealing at room temperature for 3 hr;

3) Incubation of serum samples: after sealing is finished, pouring the sealing liquid completely, then quickly adding a serum incubation liquid prepared in advance, wherein each chip can incubate 14 serum samples, the sample loading volume of each serum sample is 200 mu L, and the shaking table is laterally swung at 20rpm and incubated overnight at 4 ℃ (the serum samples are frozen and thawed in a chromatography cabinet at 4 ℃, and the incubation liquid is added to dilute in a ratio of 1: 50 to obtain the serum incubation liquid);

4) Cleaning: the chip and the chip enclosure are taken out together, the sample is sucked, then the PBST with the same volume is added rapidly, and the circulation is repeated for a plurality of times, so that no cross contamination exists among the serum samples when the chip enclosure is detached. After the chip fence is removed, the chip is placed in a chip cleaning box added with cleaning solution, and is cleaned for 3 times (10 min each time) by a horizontal shaking table at room temperature of 80 rpm;

5) And (3) secondary antibody incubation: transferring the chip into an incubation box added with 3mL of secondary antibody incubation liquid, laterally swinging a shaking table at 40rpm, avoiding light, and keeping the room temperature for 1 hr;

6) Cleaning: the chip was removed (note that the upper surface of the chip was not touched or scratched), and placed in a chip washing cassette containing a washing solution, and washed 3 times 10min each time, on a horizontal shaker at room temperature and 80 rpm. After the completion, the mixture is washed by ddH2O for 2 times, and each time is 10 min;

7) Drying;

8) Scanning: scanning by using a crystal core LuxScan 10K microarray chip scanner;

9) Data extraction: opening the corresponding GAL file (recording the position of protein in the chip), aligning the chip image and each array of the GAL file integrally, pressing an automatic alignment button, extracting data and storing.

Fourthly, the result

The mean expression level of the lichh 1 autoantibodies in the plasma of lung cancer patients was 139.1SNR (fluorescence signal to quantitative ratio), the mean expression level of the lichh 1 autoantibodies in the plasma of benign lung disease was 75.1SNR, and the mean expression level of the lichh 1 autoantibodies in the plasma of healthy controls was 78.9 SNR. The lung cancer group was statistically significant compared to both the benign lung disease group (p <0.05) and the healthy control group (p <0.05) (fig. 1). The ROC analysis of lung cancer group and benign disease resulted in 96.6% specificity and 20.7% sensitivity (FIG. 2); the ROC analysis of lung cancer group and healthy control gave a specificity of 96.6% and a sensitivity of 20.7% (fig. 3), indicating that the autoradioantibody of lichh 1 specifically distinguished lung cancer from benign lung disease and healthy control.

From the above results, it is clear that the difference in the levels of the LIMCH1 autoantibodies in the serum of the lung cancer patients and the non-lung cancer patients is significant, and the purpose of screening for lung cancer can be achieved by detecting the level of the LIMCH1 autoantibodies in the serum.

EXAMPLE 2 composition of the detection kit of the invention and method of use thereof

Kit composition

Detection kit (14 persons):

Second, kit using method

Same as example 1, third part- "detection of LIMCH1 autoantibodies in serum".

The kit can screen the risk of the lung cancer of the people to be detected by detecting the level of the LIMCH1 autoantibody in serum: if the level of lichh 1 autoantibodies is high (relative to healthy humans) the risk for lung cancer is high, and if the level of lichh 1 autoantibodies is low the risk for lung cancer is low. The method can be used for the auxiliary diagnosis of clinical lung cancer, provides effective basis for patients to take relevant treatment measures or decisions, and has good clinical application prospect.

Claims

1. The application of a reagent for detecting the LIMCH1 protein autoantibody in preparing a lung cancer screening kit.

2. the use of claim 1, wherein the reagent for detecting the LIMCH1 protein autoantibody is a reagent for enzyme-linked immunosorbent assay or a combined immunoassay reagent.

3. the use of claim 1, wherein the reagent for detecting an autoantibody to the LIMCH1 protein is a western blot reagent.

4. The use according to claim 1, wherein the reagent for detecting the LIMCH1 protein autoantibody is a reagent for a protein chip detection method.

5. the use of any one of claims 1 to 4, wherein the reagent for detecting the autoantibody to the LIMCH1 protein is a reagent for detecting the autoantibody to the LIMCH1 protein in human serum.

6. A lung cancer screening kit, which comprises a reagent for detecting an autoantibody to the lichh 1 protein.

7. The kit of claim 6, wherein the reagent for detecting the LIMCH1 protein autoantibody is an enzyme-linked immunosorbent assay reagent or an enzyme-linked immunoassay reagent.

8. The kit of claim 6, wherein the reagent for detecting the LIMCH1 protein autoantibody is a western blot reagent.

9. The kit of claim 6, wherein the reagent for detecting the LIMCH1 protein autoantibody is a reagent for a protein chip detection method.

10. The kit of any one of claims 5 to 9, wherein the reagent for detecting the autoantibody to the LIMCH1 protein is a reagent for detecting the autoantibody to the LIMCH1 protein in human serum.